Medivir AB (Medivir AB) Short-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Medivir AB Short-Term Capital Lease Obligation?

Medivir AB's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.

Medivir AB's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.22 Mil) but then declined from Dec. 2023 ($0.22 Mil) to Mar. 2024 ($0.00 Mil).

Medivir AB's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.12 Mil) to Dec. 2022 ($0.20 Mil) and increased from Dec. 2022 ($0.20 Mil) to Dec. 2023 ($0.22 Mil).

Medivir AB Short-Term Capital Lease Obligation Historical Data

The historical data trend for Medivir AB's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Short-Term Capital Lease Obligation Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.71

0.19

0.12

0.20

0.22

Medivir AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	0.22	-

Medivir AB Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Medivir AB Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Medivir AB's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBY) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.